Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes
Autore:
Tsubouchi, Y; Sano, H; Yamada, R; Hashiramoto, A; Kohno, M; Kusaka, Y; Kondo, M;
Indirizzi:
Kyoto Prefectural Univ Med, Dept Internal Med 1, Kamigyo Ku, Kyoto 6028566, Japan Kyoto Prefectural Univ Med Kyoto Japan 6028566 Ku, Kyoto 6028566, Japan Kyoto Prefectural Univ Med, Dept Orthoped Surg, Kamigyo Ku, Kyoto 6028566,Japan Kyoto Prefectural Univ Med Kyoto Japan 6028566 o Ku, Kyoto 6028566,Japan
Titolo Testata:
EUROPEAN JOURNAL OF PHARMACOLOGY
fascicolo: 3, volume: 395, anno: 2000,
pagine: 255 - 263
SICI:
0014-2999(20000503)395:3<255:PIOCBM>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE-1; NITRIC-OXIDE SYNTHASE; HUMAN SYNOVIAL-CELLS; SELECTIVE-INHIBITION; INDUCIBLE CYCLOOXYGENASE; ENDOTHELIAL-CELLS; MESSENGER-RNA; DIFFERENTIAL INHIBITION; ADJUVANT ARTHRITIS;
Keywords:
rheumatoid arthritis; synoviocyte; cyclooxygenase-1; cyclooxygenase-2; meloxicam;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Sano, H Kyoto Prefectural Univ Med, Dept Internal Med 1, Kamigyo Ku, 465 Kajiicho,Kyoto 6028566, Japan Kyoto Prefectural Univ Med 465 Kajiicho KyotoJapan 6028566 Japan
Citazione:
Y. Tsubouchi et al., "Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes", EUR J PHARM, 395(3), 2000, pp. 255-263

Abstract

The aim of this study was to evaluate the anti-inflammatory effect of 4-hydroxy-2-methyl-N-[5-methyl-2-thiazolyl]-2H-1,2-benzothiazine-3-carboxamide-1,l-dioxide (meloxicam) using cultured rheumatoid synovial fibroblast-like cells (synoviocytes). Synoviocytes were treated with meloxicam in the presence or absence of interleukin-1 beta. Meloxicam had no effect on both cyclooxygenase-l and -2 expression as determined by Western blot analysis, immunohistochemical staining, and reverse transcription polymerase chain reaction (RT-PCR). Even the lower doses of meloxicam inhibited cyclooxygenase-2 activity, but only the higher doses of meloxicam inhibited cyclooxygenase-l activity as determined by prostaglandin E-2 synthesis assay. So meloxicam had a preferential inhibitory effect of cyclooxygenase-2 relative to cyclooxygenase-l on cultured rheumatoid synoviocytes without affecting cyclooxygenase expression. On the other hand, indomethacin had no selectivity and dexamethasone inhibited the expression of cyclooxygenase-2. Our data indicate that clinical efficacy and safety of meloxicam for rheumatoid arthritis may result from its preferential inhibition of cyclooxygenase-2 activity relative to cyclooxygenase-l on rheumatoid synoviocytes. (C) 2000 Elsevier ScienceB.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 07:38:01